Aptorum Group Ltd Stock Today
| APM Stock | USD 0.79 0.01 0.63% |
Performance0 of 100
| Odds Of DistressOver 83
|
Aptorum Group is selling at 0.785 as of the 12th of December 2024; that is 0.63% down since the beginning of the trading day. The stock's lowest day price was 0.79. Aptorum Group has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 12th of November 2024 and ending today, the 12th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of December 2018 | Category Healthcare | Classification Health Care |
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. The company has 3.81 M outstanding shares of which 18.93 K shares are presently shorted by investors with about 0.35 days to cover. More on Aptorum Group Ltd
Moving together with Aptorum Stock
Moving against Aptorum Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Aptorum Stock Highlights
| Old Names | [Aptorum Group Ltd., APM Human Services International Ltd] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, SPASX 300, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAptorum Group can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aptorum Group's financial leverage. It provides some insight into what part of Aptorum Group's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aptorum Group Ltd (APM) is traded on NASDAQ Exchange in USA. It is located in 17 Hanover Square, London, United Kingdom, W1S 1BN and employs 3 people. Aptorum Group is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a total capitalization of 4.4 M. Aptorum Group runs under Biotechnology sector within Health Care industry. The entity has 3.81 M outstanding shares of which 18.93 K shares are presently shorted by investors with about 0.35 days to cover.
Aptorum Group Ltd has about 4.22 M in cash with (7.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12.
Check Aptorum Group Probability Of Bankruptcy
Ownership AllocationAptorum Group Ltd retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Aptorum Ownership Details
Aptorum Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 39.7 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 16 K | |
| Murchinson Ltd. | 2024-06-30 | 0.0 | |
| Tower Research Capital Llc | 2024-06-30 | 0.0 | |
| Goss Wealth Management Llc | 2024-06-30 | 0.0 | |
| Ubs Group Ag | 2024-09-30 | 0.0 | |
| Citadel Advisors Llc | 2024-09-30 | 0.0 |
Aptorum Group Historical Income Statement
Aptorum Stock Against Markets
Aptorum Group Corporate Management
| Wai Lee | Head RD | Profile | |
| Martin Siu | Head Finance | Profile | |
| Darren Lui | Chief CEO | Profile | |
| Kwok Wong | Head Finance | Profile | |
| Chung Huen | Founder Director | Profile | |
| Clark Cheng | Chief Director | Profile |
Already Invested in Aptorum Group Ltd?
The danger of trading Aptorum Group Ltd is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aptorum Group is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aptorum Group. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aptorum Group is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Aptorum Group is a strong investment it is important to analyze Aptorum Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aptorum Group's future performance. For an informed investment choice regarding Aptorum Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptorum Group Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptorum Group. If investors know Aptorum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptorum Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.62) | Revenue Per Share 0.095 | Quarterly Revenue Growth (1.00) | Return On Assets (0.32) | Return On Equity (0.37) |
The market value of Aptorum Group is measured differently than its book value, which is the value of Aptorum that is recorded on the company's balance sheet. Investors also form their own opinion of Aptorum Group's value that differs from its market value or its book value, called intrinsic value, which is Aptorum Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptorum Group's market value can be influenced by many factors that don't directly affect Aptorum Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptorum Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptorum Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptorum Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.